Bellicum Pharmaceuticals, Inc. (BLCM)
| Market Cap | 12.57M |
| Revenue (ttm) | 6.20M |
| Net Income (ttm) | -6.47M |
| Shares Out | 8.61M |
| EPS (ttm) | -0.37 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 17,908 |
| Open | 1.55 |
| Previous Close | 1.55 |
| Day's Range | 1.42 - 1.55 |
| 52-Week Range | 1.34 - 4.04 |
| Beta | 1.45 |
| Analysts | Buy |
| Price Target | 5.10 (+249.3%) |
| Earnings Date | May 16, 2022 |
About BLCM
Bellicum Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel cellular immunotherapies for the treatment of hematological cancers and solid tumors in the United States and internationally. The company's clinical product candidates include BPX-601, an autologous GoCAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of solid tumors expressing the prostate stem cell antigen; and BPX-603, a dual-switch GoCAR-T product candidate that is in Phase 1/2 clinical trial...
Financial Performance
In 2021, BLCM's revenue was $6.20 million, an increase of 1,140.00% compared to the previous year's $500,000. Losses were -$9.71 million, 25.7% more than in 2020.
Financial StatementsAnalyst Forecast
According to 7 analysts, the average rating for BLCM stock is "Buy." The 12-month stock price forecast is 5.1, which is an increase of 249.32% from the latest price.
News
Bellicum Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
HOUSTON, May 02, 2022 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced equity inducement...
Bellicum Reports Fourth Quarter 2021 Financial Results and Provides Operational Update
- Confirmed partial response in one of the first three metastatic castration-resistant prostate cancer (mCRPC) patients treated with BPX-601 in Phase 1/2 study -
Bellicum Pharmaceuticals to Participate in the B. Riley Securities 2022 Virtual Oncology Conference
HOUSTON, Jan. 26, 2022 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced that Rick Fair,...
Bellicum Regains Compliance with Nasdaq Continued Listing Requirements
HOUSTON, Dec. 13, 2021 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced that it has rec...
Bellicum Secures $35M Via Equity Funding, Posts Interim Data From Early GoCAR-T Cancer Studies
Bellicum will issue pre-funded warrants to purchase up to 20.6 million shares and accompanying warrants to purchase up to 2.06 million shares at a combined unit price of $1.7024. Warrants have an exerci...
Bellicum Reports Third Quarter 2021 Financial Results and Provides Operational Update
- Entered into additional licensing agreement with The University of Texas MD Anderson Cancer Center for use of CaspaCIDe® safety switch technology -
Bellicum Pharmaceuticals to Participate in the H.C. Wainwright 23rd Annual Global Investment Conference
HOUSTON, Sept. 03, 2021 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced that Rick Fair,...
Why Is Bellicum Stock Moving Higher On Wednesday?
Bellicum Pharmaceuticals Inc (NASDAQ: BLCM) and The University of Texas MD Anderson Cancer Center have announced a global option and license agreement for Bellicum's CaspaCIDe (inducible caspase-9, or i...
Bellicum and MD Anderson Announce Additional License Agreement for Use of CaspaCIDe® Safety Switch
HOUSTON, Sept. 01, 2021 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, and The University of Texas MD ...
Bellicum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
HOUSTON, July 26, 2021 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced an equity induce...
Bellicum Enters License Agreement with UNC Lineberger and Mass General for Use of CaspaCIDe® Safety Switch
HOUSTON, June 28, 2021 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced it has entered i...
Bellicum Reports First Quarter 2021 Financial Results and Provides Operational Update
HOUSTON, May 17, 2021 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today reported financial results...
Bellicum Reports Fourth Quarter 2020 Financial Results and Provides Operational Update
Enrolled first patient in Phase 1/2 clinical trial for BPX-603 in solid tumors that express HER2
Bellicum to Report Fourth Quarter and Full Year 2020 Financial Results and Provide Corporate Update
Management to host webcast and conference call on Tuesday, March 30, 2021 at 5 p.m. ET / 2 p.m. PT Management to host webcast and conference call on Tuesday, March 30, 2021 at 5 p.m. ET / 2 p.m. PT
Bellicum Announces First Reported Use of CaspaCIDe® Safety Switch to Mitigate CAR-T Cell Toxicity
HOUSTON, March 04, 2021 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced the publication...
Bellicum Reports FDA Lifted Clinical Hold on BPX-601 Phase 1/2 Clinical Trial
HOUSTON, Jan. 28, 2021 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced that the U.S. Fo...
Bellicum Pharmaceuticals (BLCM) Upgraded to Buy: Here's Why
Bellicum Pharmaceuticals (BLCM) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Bellicum Enrolls First Patient in Phase 1/2 Clinical Trial for BPX-603
HOUSTON, Dec. 10, 2020 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced enrollment and a...
Bellicum Reports Clinical Hold Placed on BPX-601 Phase 1/2 Clinical Trial
HOUSTON, Dec. 07, 2020 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced that it has been...
Bellicum Pharmaceuticals (BLCM) Upgraded to Buy: Here's What You Should Know
Bellicum Pharmaceuticals (BLCM) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Rising P/E: An Ignored Trick to Pick 5 Winning Stocks
Want to try an out-of-the-box approach? Tap five stocks with increasing P/E ratios.
Bellicum Reports Third Quarter 2020 Financial Results and Provides Operational Update
Strategic focus on clinical GoCAR-T ® programs with plans to initiate Phase 1/2 enrollment of BPX-601 in mCRPC and BPX-603 in HER2+ solid tumors by end of year
Bellicum Pharmaceuticals Announces Closing of $25.0 Million Underwritten Offering
HOUSTON, Nov. 03, 2020 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced the closing of i...
Bellicum Pharmaceuticals to cut 79% of staff after disappointing trial data, stock suffering record plunge
Shares of Bellicum Pharmaceuticals Inc. plunged 35.1% in midday trading Friday, putting them on track for their biggest-ever one-day drop, after the clinical stage biopharmaceutical company said it was ...